All In Biotech

Drug Trial Radar · NCT06416865

Efficacy and Safety of AJU-C52 in Essential Hypertension Patients

A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of AJU-C52 in Compared With C52R1M for Essential Hypertension Patients in Inappropriately Controlled on C52R1L Treatment

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 193 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

193

Actual

Start

Oct 18, 2022

Primary completion

Dec 23, 2024

Study completion Feb 19, 2025

Sponsor

Lead sponsor
AJU Pharm Co., Ltd.Industry
Sponsor type
Industry
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately controlled on C52R1L treament

Conditions

  • Essential Hypertension

Interventions

  • AJU-C52L, AJU-C52Drug

    AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks. AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks.

  • C52R1L, C52R1MDrug

    C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks. C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in MSSBP(mean sitting systolic blood pressure)Time frame: 8th week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • AJU Pharm Co., Ltd.

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.